Compare Incyte Corporation (INCY) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Direxion Daily TSLA Bull 2X Shares trades at $10.4 (market cap $3.97B). The key difference: Incyte Corporation is far larger — about 5.8× Direxion Daily TSLA Bull 2X Shares's market cap, and Incyte Corporation is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| INCY | TSLL | |
|---|---|---|
Market Cap | $22.85B | $3.97B |
Volume | 1,927,029 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.93 | $23.03 |
52-Week Low | $83.80 | $6.74 |
Typical Hold Time | 33 Days | 15 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
TSLL, a leveraged ETF tracking Tesla, trades at $10.01, down 1.38% amid neutral technical signals. Moving averages suggest a bullish trend, but RSI indicates overbought conditions. The ETF lacks traditional financial ratios due to its structure, and recent news highlights its volatility tied to Tesla's Cybercab event.
Outlook hinges on Tesla's performance, offering amplified gains but high risk from daily rebalancing. Investors face significant volatility and potential decay, requiring careful risk management given the leveraged nature and dependence on Tesla's stock movements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
